The following video is part of our "Motley Fool Conversations" series, in which analyst John Reeves and advisor David Meier discuss topics around the investing world.
John and David have been thinking of buying additional shares of MAKO Surgical. But they wanted to wait until management gave more information in its earnings release. Here's what they learned. First, despite the decline in system sales growth, procedures increased 66%. Doctors are using the systems. Second, the company continues to update its software, improving the process. Finally, the company has sold systems into larger hospital chains. That's a sign of progress.
MAKO Surgical is making strides, but it isn't humming on all cylinders. It's clear that robotic surgery is still young, though it is progressing. Just look at, for example, Intuitive Surgical, Staar Surgical, Hansen Medical, and even rumblings from Stryker. John and David think it's worth buying a few shares at today's price, even if the clouds haven’t fully lifted.
The recent market sell-off of MAKO Surgical shares has many wondering whether the potential growth prospects of the robotic-surgery company make it a buy today or a stock to stay away from. John and David think it's the former, but investors may want to consider both sides of the debate. Read our premium report to read up on the details of MAKO's story. Click here to access it now.
David Meier and John Reeves have no positions in the stocks mentioned above. The Motley Fool owns shares of Intuitive Surgical and MAKO Surgical. Motley Fool newsletter services recommend Intuitive Surgical, MAKO Surgical , and Stryker. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
The Top 3 Dividend Aristocrats to Watch in 2018
Big news in the coming year could send these stocks higher or threaten their payouts.
These 3 Stocks Just Raised Their Dividends
There isn't much time left for companies to get in their last payout hikes of 2017. This trio made it with only weeks to spare.
Why Stryker, Ultragenyx Pharmaceutical, and La-Z-Boy Slumped Today
These stocks helped put downward pressure on the market. Find out why.